Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GT Biopharma (GTBP)
NASDAQ:GTBP
Holding GTBP?
Track your performance easily
GTBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.92 - $10.66
Previous Close$3.06
Volume12.05K
Average Volume (3M)18.26K
Market Cap
$6.84M
Enterprise Value$419.04K
Total Cash (Recent Filing)$6.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.48
Shares Outstanding2,234,328
10 Day Avg. Volume31,865
30 Day Avg. Volume18,262
Standard Deviation0.33
R-Squared0.00797
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.39
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
GT Biopharma News
PremiumCompany Announcements
GT Biopharma’s Dr. Miller Assumes New Medical Director Role
PremiumCompany Announcements
GT Biopharma Announces CFO Transition and New Financial Leadership
Ownership Overview
―
Insiders
1.05% Mutual Funds
<0.01% Other Institutional Investors
98.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $1.92 and its highest was $10.66 in the past 12 months.
What is GT Biopharma’s market cap?
Currently, no data Available
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is May 19, 2025 which is in 176 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Nov 14, 2024. The company reported -$1.527 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.527.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 2,234,328 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$1.527 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.99%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
---
GT Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.97%
12-Months-Change
Fundamentals
Return on Equity
-204.08%
Trailing 12-Months
Asset Growth
-58.14%
Trailing 12-Months
Company Description
GT Biopharma
GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Westlake Village, CA.
---
GTBP Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Karyopharm Therapeutics
―
MacroGenics
―
Nektar Therapeutics
―
---